We report on a 67-year-old women with rheumatoid arthritis who developed an afebrile erysipelas during treatment with tumor necrosis factor (TNF) receptor fusion protein (etanercept). The medication was interrupted, following that the patient developed fever. The erysipelas was cured with amoxicilline and flucloxacilline. The therapy with etanercept was then re-started. Patients treated with TNF-blocking agents who develop an erysipelas may stay afebrile and therefore cause diagnostic difficulties.
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